June 24, 2021
3 min watch
Save
VIDEO: Cost-effectiveness analyses of adjuvant osimertinib uses data from ADAURA trial
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Nathan A. Pennell, MD, PhD, spoke with Healio about a study he co-authored that was presented at virtual ASCO Annual Meeting.
Pennell, medical oncologist at the Cleveland Clinic and associate professor medical oncology at the Cleveland Clinic Lerner College, and colleagues developed a cost-benefit analyses model using data from the ADUARA trial. They looked at the cost-effectiveness of adjuvant osimertinib therapy for patients with resected EGFR-mutant non-small cell lung cancer and discovered “that the drug would likely not be cost effective.”
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview; Lemmon C, et al. Abstract 9004. Presented at: ASCO Annual Meeting (virtual meeting); June 4-8, 2021.
Disclosures:
Disclosure: Pennell reports serving in a consulting or advisory role for Bristol Myer Squibb, Genentech and Janssen.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.